COVID-19 Antibody Assay Reagents
FOR RESEARCH USE ONLY
Veravas can help advance your research in infectious disease and vaccine efficacy with the ability to perform highly sensitive COVID-19 neutralizing antibody testing in serum and saliva (Swish-N-Spit).
Select from our different SARS-CoV-2 antigen coated beads and available RUO reagents to quantitatively measure IgG, IgM, and IgA immunoglobulins in a single test with high sensitivity and specificity.
Built on the Veravas Platform
Increased Specificity: Our proprietary, magnetic nanobead reagent removes interferences and lowers background noise of an assay.
High Sensitivity: VERAVAS® can use multiple antigen epitopes to increase likelihood of detection and performs a novel concentration or enrichment step to increase sensitivity.
True Quantitative Measurement: VERAVAS uses proprietary calibration method to measure the concentration of antibodies in serum/plasma (μg/mL) or saliva (ng/mL). Compared to other assay methods that measure a reference unit that is not consistent among assays.
Measure 3 Immunoglobulins: Most assays only look at one or two antibody types. By quantifying IgG, IgM, AND IgA in a single instance or over time can provide new insight to the body’s immune system response to SARS-CoV-2 or other pathogens.
Performance Data - Serum
Sensitivity Compared to Other Serology Tests
Veravas demonstrated higher sensitivity compared against serology tests from Abbott, Beckman, Roche, and Siemens.
Serum to Saliva Sample Type Agreement
Veravas saliva sample performance has near exact concordance with our serum protocol. Veravas offers the best test and sample type.
Performance Data - Saliva
The high specificity and sensitivity of the Veravas COVID-19 Antibody test makes it possible to detect antibodies in a saliva sample with 100% specificity and >95% sensitivity as early as 2 days from symptom onset. (Blood-based tests typically take 14 days to achieve the same sensitivity).
Positive Agreement by Days Post-Symptom Onset
The clinical sensitivity of the Access Genetics, LLC immun19™ COVID-19 Antibody Test was evaluated by testing saline oral rinse samples that were RT-PCR positive by the OraRisk COVID-19 RT-PCR (EUA200464). Positive saline oral rinse samples were prospectively collected from unvaccinated patients who tested positive for SARS-CoV-2 by OraRisk COVID-19 RT-PCR with known days after symptom onset.
Saline Oral Rinse and Saliva Negative Agreement
The clinical specificity of the Access Genetics, LLC immun19™ COVID-19 Antibody Test was evaluated by testing frozen saliva samples collected prior to November 2019 and by testing presumptive negative saline oral rinse samples that were prospectively collected from patients that met the study inclusion criteria.
Clinical Performance 0-7 Days Post-Symptom Onset
The Access Genetics, LLC immun19™ COVID-19 Antibody Test detected neutralizing secretory antibodies against SARS-CoV-2 spike protein RBD and NTD with 96% sensitivity as early as the day of symptom onset. In comparison, the majority of serum-based serology tests do not demonstrate > 95% sensitivity until 15 or more days after PCR positive results.
Select SARS-CoV-2 RUO Antigen Reagents To Customize Your Test
SARS-CoV-2 (B.1.1.28) Spike Glycoprotein (S1) RBD, His-Tag (HEK293), BRAZILIAN (GAMMA) VARIANT
SARS-CoV-2 (N501Y Mutant) Spike Glycoprotein (S1) RBD, His-Tag (HEK293), UNITED KINGDOM (ALPHA) VARIANT
SARS-CoV-2 (B.1.617.2) Spike Glycoprotein (S1) RBD, His-Tag (HEK293), INDIAN (DELTA) VARIANT
SARS-CoV-2 Spike Glycoprotein (S1) RBD, His-Tag (HEK293)
SARS-CoV-2 (C.37: L452Q, F490S) Spike Glycoprotein (S1) RBD, His-Tag (HEK293), LAMBDA VARIANT
SARS-CoV-2 (B.1.351/501Y.V2) Spike Glycoprotein (S1) RBD, His-Tag (HEK293), SOUTH AFRICAN (BETA) VARIANT
SARS-CoV-2 (B.1.617.1) Spike Glycoprotein (S1) RBD, His-Tag (HEK293), KERALA (KAPPA) VARIANT
SARS-CoV-2 Omicron BA.5 RBD, C-terminal His-tag, OMICRON VARIANT
SARS-CoV-2 RBD-Nucleoprotein Chimera, His-Tag (CHO)
SARS-CoV-2 (B.1.1.529/Omicron) Spike Glycoprotein (S1) RBD, His-Tag (HEK293), OMICRON VARIANT
SARS-CoV-2 (B.1.1.7) Spike Glycoprotein (Full-Length), His-Tag (HEK293), UNITED KINGDOM (ALPHA) VARIANT
SARS-CoV-2 (B.1.1.7 + E484K) Stabilized Spike Glycoprotein (Full-Length), His-Strep-Tag (HEK293), UNITED KINGDOM (ALPHA) VARIANT
SARS-CoV-2 (N501Y, D614G Mutant) Spike Glycoprotein (S1), Sheep Fc-Tag (HEK293)
SARS-CoV-2 (B.1.1.7) Stabilized Spike Glycoprotein (Full-Length), His-Strep-Tag (HEK293), UNITED KINGDOM (ALPHA) VARIANT
SARS-CoV-2 Spike N-Terminal Domain (NTD), His-Tag (HEK293)
SARS-CoV-2 Spike N-Terminal Domain (NTD), Sheep Fc-Tag (HEK293)
SARS-CoV-2 (C.37) Stabilized Spike Glycoprotein (Trimeric), His-Strep-Tag (HEK293), LAMBDA VARIANT
SARS-CoV-2 (B.1.351) Stabilized Spike Glycoprotein (Trimeric), His-Strep-Tag (HEK293), SOUTH AFRICAN (BETA) VARIANT
SARS-CoV-2 (B.1.351/501.V2) Stabilized Spike Glycoprotein (Full-Length), His-Strep-Tag (HEK293), SOUTH AFRICAN (BETA) VARIANT
SARS-CoV-2 (A222V Mutant) Spike Glycoprotein (S1), Sheep Fc-Tag (HEK293)
SARS-CoV-2 Stabilized Spike Glycoprotein (Full-Length), His-Strep-Tag (HEK293)
SARS-CoV-2 Spike Glycoprotein (S2), His-Tag (Insect Cells)
SARS-CoV-2 Spike Glycoprotein (S1), His-Tag (Insect Cells)
SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag (HEK293)
SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag (HEK293)
SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag (CHO)
SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag (CHO)
SARS-CoV-2 (S477N, D614G Mutant) Spike Glycoprotein (S1), Sheep Fc-Tag (HEK293)
SARS-CoV-2 (D614G Mutant) Spike Glycoprotein (S1), Sheep Fc-Tag (HEK293)
SARS-CoV-2 (V445I, E583D, D614G, H655Y Mutant) Spike Glycoprotein (S1), Sheep Fc-Tag (HEK293)
SARS-CoV-2 (E484K, D614G Mutant) Spike Glycoprotein (S1), Sheep Fc-Tag (HEK293)
SARS-CoV-2 (G485R, D614G Mutant) Spike Glycoprotein (S1), Sheep Fc-Tag (HEK293)
SARS-CoV-2 (L84I, N439K, D614G Mutant) Spike Glycoprotein (S1), Sheep Fc-Tag (HEK293)
SARS-CoV-2 Spike Glycoprotein (S2) (aa 1000-1200), His-Tag (E. coli)
SARS-CoV-2 Spike Glycoprotein (S2) (aa 800-1000), His-Tag (E. coli)
SARS-CoV-2 (B.1.1.529/Omicron) Spike Glycoprotein (S1), Sheep Fc-Tag (HEK293), OMICRON VARIANT
SARS-CoV-2 (B.1.1.529/Omicron) Stabilized Spike Glycoprotein (Trimeric), His-Strep-Tag (HEK293), OMICRON VARIANT
SARS-CoV-2 (N439K Mutant) Spike Glycoprotein (S1), Sheep Fc-Tag (HEK293)
Human ACE2 (18-615) Recombinant Protein, Sheep Fc-Tag (HEK293)
Human ACE2 (19-740) Recombinant Protein, Fc-Tag (CHO)
Human ACE2 (18-615) Recombinant Protein, Fc-Tag (CHO)
Human CD147 (22-205) Recombinant Protein, Fc-Tag (CHO)
Human Coronavirus 229E Purified Viral Lysate
SARS-CoV-2 (B.1.1.529/Omicron) Nucleoprotein, His-Tag (E. coli)
SARS-CoV-2 RBD-Nucleoprotein Chimera, His-Tag (CHO)
SARS-CoV-2 Spike-E-M Mosaic Protein, His-Tag (E. coli)
SARS-CoV-2 Purified Viral Lysate
SARS-CoV-2 Nucleoprotein, His-Tag (E. coli)
Human CD147 (BSG) Recombinant Protein, His-Tag (HEK293)
Human CD147 (22-205) Recombinant Protein, Fc-Tag (CHO)
Human Coronavirus HKU1 Nucleoprotein, His-Tag (E. coli)
Human Coronavirus HKU1 Spike Glycoprotein (S1), His-Tag (HEK293)
Human Coronavirus 229E Purified Viral Lysate
Human Coronavirus HKU1 Spike Glycoprotein (Full-Length), Sheep Fc-Tag (HEK293)
Whether you are building a new assay or enhancing your existing test, VERAVAS® technology is easy to implement into your current testing workflow
For Research Use Only. Not for use in diagnostic procedures. Buyer acknowledges that certain Veravas’ Products are labeled and intended FOR RESEARCH USE ONLY (RUO) and not for human or animal therapeutic or diagnostic use. Buyer agrees that if it elects to use an RUO Product for a purpose, including any therapeutic or diagnostic use, that the Buyer is solely responsible for establishing, specifying, verifying and/or validating any and all functional and performance metrics. In addition, Buyer agrees that if it elects to use an RUO Product for a purpose that would subject Buyer, its customers or any RUO labeled Product to the application of regulatory agency clearance or approval, Buyer shall be solely responsible for obtaining any required approvals.